• Connect with us
  • Information
    • About Us
    • Contact Us
    • Careers
    • Partnerships
    • Advertise With Us
    • Authors
    • Browse Topics
    • Events
    • Disclaimer
    • Privacy Policy
  • Australia
    North America
    World
Login
Investing News NetworkYour trusted source for investing success
  • North America
    Australia
    World
  • My INN
Videos
Companies
Press Releases
Private Placements
SUBSCRIBE
  • Reports & Guides
    • Market Outlook Reports
    • Investing Guides
  • Button
Resource
  • Precious Metals
  • Battery Metals
  • Base Metals
  • Energy
  • Critical Minerals
Tech
Life Science
Medical Device Market
Medical Device News
Medical Device Stocks
  • Medical Device Market
  • Medical Device News
  • Medical Device Stocks
medical device investing

Eyecarrot Announces Closing of Financing

Written by Investing News Network
|
Mar. 20, 2018 03:01PM PST

Eyecarrot Innovations Corp (TSXV:EYC, | OTCQB:EYCCF), is pleased to announce the closing of a previously announced non-brokered private placement for total proceeds of $406,750. The Company issued a total of 2,711,667 units at $0.15 per unit, each unit comprised of one common share of the Company (a “Share”) and one transferable common share purchase warrant.

Eyecarrot Innovations Corp (TSXV:EYC, | OTCQB:EYCCF), is pleased to announce the closing of a previously announced non-brokered private placement for total proceeds of $406,750. The Company issued a total of 2,711,667 units at $0.15 per unit, each unit comprised of one common share of the Company (a “Share”) and one transferable common share purchase warrant. Each warrant entitles the holder to purchase one additional common share of the Company (a “Warrant Share”) until March 20, 2020 at a purchase price of $0.30 per Warrant Share.

There were no finder’s fees payable.

All securities issued in connection with the Private Placement are subject to a four-month hold period expiring on July 21, 2018. Further restrictions may apply to certain subscribers under foreign securities laws.

Proceeds of the Placement are to be applied to general working capital.

About Eyecarrot

Eyecarrot’s BinoviTM platform is an innovative healthcare technology solution that integrates software, hardware, data and expert knowledge. Binovi helps Optometrists treat vision issues with in-office therapy as well as doctor led home based activities to better serve and increase the patient’s experience and their therapy needs. The goal is to help transform vision performance for the 1 in 4 people worldwide that suffer from vision-related issues going beyond visual acuity. The company is transforming how vision healthcare services are integrated, while addressing key challenges in the health system. Eyecarrot’s objective is to help Optometrists and their teams manage a wide range of problems involving visual function. The building of this network will revolutionize human vision performance, and release the untapped potential of millions of people, globally.

On behalf of the Board of Directors

Adam Cegielski

President | CEO

Telephone: 1.855.416.7158 – 416.943.6271

Forward looking information

Certain statements contained in this news release constitute “forward-looking information” as such term is used in applicable Canadian securities laws. Forward-looking information is based on plans, expectations, and estimates of management at the date the information is provided and is subject to certain factors and assumptions, including, that the Company’s financial condition and development plans do not change as a result of unforeseen events and that the Company obtains regulatory approval. Forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause plans, estimates and actual results to vary materially from those projected in such forward-looking information. Factors that could cause the forward-looking information in this news release to change or to be inaccurate include, but are not limited to, the risk that any of the assumptions referred to prove not to be valid or reliable, that occurrences such as those referred to above are realized and result in delays, or cessation in planned work, that the Company’s financial condition and development plans change, and delays in regulatory approval, as well as the other risks and uncertainties applicable to the Company as set forth in the Company’s continuous disclosure filings filed under the Company’s profile at www.sedar.com . The Company undertakes no obligation to update these forward-looking statements, other than as required by applicable law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Click here to connect with Eyecarrot Innovations Corp (TSXV:EYC) for an Investor Presentation.

Source: www.thenewswire.com

board of directors regulatory approval eyecarrot innovations private placement medical device investing
The Conversation (0)

Go Deeper

AI Powered
Ocumetics Reports Encouraging One-Month Postoperative Results

Ocumetics Reports Encouraging One-Month Postoperative Results

Ocumetics Technology

Ocumetics Technology

Latest News

Outlook Reports world

Resource
  • Precious Metals
    • Gold
    • Silver
  • Battery Metals
    • Lithium
    • Cobalt
    • Graphite
  • Energy
    • Uranium
    • Oil and Gas
  • Base Metals
    • Copper
    • Nickel
    • Zinc
  • Critical Metals
    • Rare Earths
  • Industrial Metals
  • Agriculture
Tech
    • Artificial Intelligence
    • Cybersecurity
    • Gaming
    • Cleantech
    • Emerging Tech
Life Science
    • Biotech
    • Cannabis
    • Psychedelics
    • Pharmaceuticals

Featured Medical Device Investing Stocks

Cleo Diagnostics

Cleo Diagnostics (COV:AU)
COV:AU

Ocumetics Technology

Ocumetics Technology (OTC:CC)
OTC:CC

Bloom Health Partners

Bloom Health Partners (BLMH:CC)
BLMH:CC

Avricore Health

Avricore Health (AVCR:CC)
AVCR:CC
More featured stocks

Browse Companies

Resource
  • Precious Metals
  • Battery Metals
  • Energy
  • Base Metals
  • Critical Metals
Tech
Life Science
MARKETS
COMMODITIES
CURRENCIES